Literature DB >> 20645068

The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model.

Camille Sureau1.   

Abstract

Worldwide, it is estimated that more than 350 million people are chronically infected with hepatitis B virus (HBV), approximately 15 million of whom are coinfected with hepatitis D virus (HDV), a satellite of HBV that uses the envelope proteins of the latter to assemble its infectious particles. For a long time after HBV discovery, research on the viral life cycle, viral entry in particular, has been hampered by the lack of practical tissue culture systems. To date, in vitro isolation and serial propagation of HBV are still problematic, but the examination of the entire HBV life cycle is possible using two separate systems: (i) permissive human hepatoma cell lines to study HBV DNA replication, viral transcription, translation, assembly, and release of viral particles and (ii) primary cultures of human or chimpanzee hepatocytes or the susceptible HepaRG cell line for viral entry examination. The experimental model described here for analyzing the function of HBV envelope proteins at viral entry is based on this dual tissue culture system, in which HDV is substituted to HBV for practical reasons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645068     DOI: 10.1007/978-1-60761-688-7_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Hepatitis delta virus: A fascinating and neglected pathogen.

Authors:  Celso Cunha; João Paulo Tavanez; Severin Gudima
Journal:  World J Virol       Date:  2015-11-12

2.  Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.

Authors:  Joana Dias; Julia Hengst; Tiphaine Parrot; Edwin Leeansyah; Sebastian Lunemann; David F G Malone; Svenja Hardtke; Otto Strauss; Christine L Zimmer; Lena Berglin; Thomas Schirdewahn; Sandra Ciesek; Nicole Marquardt; Thomas von Hahn; Michael P Manns; Markus Cornberg; Hans-Gustaf Ljunggren; Heiner Wedemeyer; Johan K Sandberg; Niklas K Björkström
Journal:  J Hepatol       Date:  2019-05-14       Impact factor: 25.083

3.  The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies.

Authors:  Liesbeth Ceelen; Marusya Lieveld; Ramses Forsyth; Mathieu Vinken
Journal:  Hepatol Int       Date:  2013-02-14       Impact factor: 6.047

4.  Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Authors:  Frauke Beilstein; Matthieu Blanchet; Andrew Vaillant; Camille Sureau
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

5.  Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies.

Authors:  Romain Julithe; Georges Abou-Jaoudé; Camille Sureau
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

Review 6.  Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions.

Authors:  Rafael Aldabe; Lester Suárez-Amarán; Carla Usai; Gloria González-Aseguinolaza
Journal:  Pathogens       Date:  2015-02-12

7.  A novel toolbox for the in vitro assay of hepatitis D virus infection.

Authors:  Jing-Hua Zhao; Ya-Li Zhang; Tian-Ying Zhang; Lun-Zhi Yuan; Tong Cheng; Pei-Jer Chen; Quan Yuan; Ning-Shao Xia
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

8.  Comparative proteomics reveals novel components at the plasma membrane of differentiated HepaRG cells and different distribution in hepatocyte- and biliary-like cells.

Authors:  Catalina Petrareanu; Alina Macovei; Izabela Sokolowska; Alisa G Woods; Catalin Lazar; Gabriel L Radu; Costel C Darie; Norica Branza-Nichita
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

9.  Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).

Authors:  Isabel Veloso Alves Pereira; Bettina Buchmann; Lisa Sandmann; Kathrin Sprinzl; Verena Schlaphoff; Katinka Döhner; Florian Vondran; Christoph Sarrazin; Michael P Manns; Cláudia Pinto Marques Souza de Oliveira; Beate Sodeik; Sandra Ciesek; Thomas von Hahn
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

10.  Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.

Authors:  Eloi R Verrier; Che C Colpitts; Charlotte Bach; Laura Heydmann; Laetitia Zona; Fei Xiao; Christine Thumann; Emilie Crouchet; Raphaël Gaudin; Camille Sureau; François-Loïc Cosset; Jane A McKeating; Patrick Pessaux; Yujin Hoshida; Catherine Schuster; Mirjam B Zeisel; Thomas F Baumert
Journal:  Cell Rep       Date:  2016-10-25       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.